• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Conclusions: Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk.
Source: Cardiovascular Diabetology - February 4, 2014 Category: Cardiology Authors: Nayyar IqbalArtist ParkerRobert FrederichMark DonovanBoaz Hirshberg Source Type: research

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research

Could exercise be as effective as medication?
Conclusion The researchers found that there are very few trials that directly compare exercise with drug therapy for any condition. They were only able to find enough trials to be able to analyse results for four major conditions. They found that exercise reduced death rates for people after a stroke (although this analysis has limitations and should be interpreted cautiously), and that drug therapy with diuretics improved death rates for people with heart failure. They did not find any difference between exercise and drug therapy for death rates after a heart attack or in people with pre-diabetes. There were several limit...
Source: NHS News Feed - October 2, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Heart/lungs Medication Source Type: news

Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin. PMID: 24089540 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - September 10, 2013 Category: Endocrinology Authors: N. M. Scheller, U. M. Mogensen, C. Andersson, A. Vaag, C. Torp‐Pedersen Tags: ORIGINAL ARTICLE Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research

Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
ConclusionsResults suggest that sulphonylurea use may elevate the risk of cardiovascular disease among patients with diabetes. This meta‐analysis expands the pool of studies evaluating cardiovascular mortality compared with prior observations while using adjusted estimates, and assessing an additional outcome of a composite cardiovascular event. This finding warrants consideration in clinical practice when other treatment options may be available.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 11, 2013 Category: Endocrinology Authors: O. J. Phung, E. Schwartzman, R. W. Allen, S. S. Engel, S. N. Rajpathak Tags: Review Source Type: research

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus†
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes.
Conclusions: In people with T2DM, exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline characteristics between treatment groups should be considered when interpreting these results. PMID: 23372169 [PubMed - in process]
Source: The Journal of Clinical Endocrinology and Metabolism - February 1, 2013 Category: Endocrinology Authors: Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL Tags: J Clin Endocrinol Metab Source Type: research

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11